

## **Acutus Medical Reports Second Quarter 2020 Financial Results**

September 17, 2020

CARLSBAD, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (Nasdaq: AFIB), today reported financial results for its second quarter ended June 30, 2020.

#### **Recent Highlights:**

- Reported revenue of \$1.1 million in the second quarter of 2020, a 54% increase over the same quarter last year and within the preliminary range disclosed in our initial public offering ("IPO") prospectus.
- Increased worldwide installed base of AcQMap consoles to 38 as of June 30, 2020, up from 31 at the end of the prior quarter. Of those 38 consoles, 21 were 2<sup>nd</sup> generation machines, up from 11 at the end of the prior quarter.
- During August, completed an initial public offering of 10.1 million shares, raising \$163.3 million in net proceeds.

"In light of the challenging circumstances experienced by medical device companies generally during the first half of 2020, I'm very pleased with our second quarter results and the dedication demonstrated by our team to our mission of improving the efficiency and effectiveness of arrhythmia treatment," said Vince Burgess, President and Chief Executive Officer. "While we did see widespread interruptions to hospital electrophysiology services in the US and Europe due to the COVID-19 pandemic, we nevertheless saw strong console placements in the second quarter. We also saw many of our EP customers begin to re-open their labs in the latter half of Q2, driving an encouraging trend toward recovery to procedure rates, so we feel well positioned as we look to continue our growth."

#### Second Quarter 2020 Financial Results

Revenue was \$1.1 million for the second quarter of 2020, compared to \$1.6 million for the prior quarter and \$0.7 million for the second quarter of 2019, and within the preliminary range disclosed in our IPO prospectus. Headwinds from the global pandemic drove a procedural decline during the second quarter of 2020 relative to the first quarter of 2020. The increase in revenue when compared to the second quarter of 2019 was driven by increased disposables sales associated with the expansion of our AcQMap console installed base as we initiated our full commercial launch.

Gross margin was negative 135% for the second quarter of 2020, compared with negative 232% in the same quarter last year. The improvement was driven by greater production volumes and efficiencies in labor and manufacturing overhead absorption when compared to the same period last year. Over time and in advance of our full commercial launch, we have made significant investments in our manufacturing infrastructure to support our commercial launch in order to position us to scale production in-house as our business grows. As volumes increase over time, we expect to see the benefit of these investments and improvements to our margin profile.

Operating expenses were \$17.9 million for the second quarter of 2020, compared with \$12.2 million in the same quarter last year. The increase was driven primarily due to the expansion of our commercial team in conjunction with our full commercial launch, various R&D projects related to console enhancements and catheter development programs, and increased G&A costs incurred in anticipation of our becoming a public company.

We effected a 1-for-9.724 reverse split of our capital stock on July 28, 2020 in anticipation of our IPO. We have retrospectively adjusted outstanding shares to reflect the impact of the reverse stock split for all periods presented. Net loss was \$23.2 million for the second quarter of 2020 and net loss per share was \$32.24 on a weighted-average basic and diluted outstanding share count of 0.72 million, compared to \$30.3 million and a net loss per share of \$45.70 on a weighted-average basic and diluted outstanding share count of 0.66 million in the same period of the prior year. It is important to note these figures are based on pre-IPO share counts and do not reflect the conversion of 16.6 million shares of convertible preferred stock to common nor the issuance of 10.1 million common shares at the IPO. Beginning in the third quarter of 2020, these 26.7 million shares will be included in our calculation of weighted-average basic and diluted share counts, which will significantly reduce our net loss per share for future reporting periods as compared to reporting periods prior to our IPO.

Cash, cash equivalents, marketable securities and restricted cash were \$29.5 million as of June 30, 2020, which excludes the \$163.3 million net proceeds from our IPO, which closed on August 10, 2020.

## **Outlook and COVID-19**

Due to uncertainty surrounding the COVID-19 pandemic, Acutus Medical will not provide financial guidance for the remainder of 2020 at this time. Management will continue to evaluate its guidance policies and anticipates providing an update at the time of its third quarter earnings announcement, to the extent practicable, based on available information at that time.

#### **Webcast and Conference Call Information**

Acutus Medical will host a conference call to discuss the second quarter financial results after market close on Thursday, September 17, 2020 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 570-1131 for U.S. callers or (914) 987-7078 for international callers, using conference ID: 9767216. The live webinar can be accessed at <a href="https://ir.acutusmedical.com">https://ir.acutusmedical.com</a>.

#### About Acutus Medical, Inc.

Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions, and global partnerships, Acutus has established a global

sales presence delivering a broad portfolio of highly differentiated electrophysiology products. Acutus Medical's goal is to provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias in each of its geographic markets. Founded in 2011, Acutus is based in Carlsbad, California.

#### **Caution Regarding Forward-Looking Statements**

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact: Caroline Corner Westwicke ICR D: 415-314-1725

Caroline.corner@westwicke.com

Holly Windler
M: 619-929-1275

media@acutusmedical.com

### Acutus Medical, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands)

Current assets:         \$ 24,295         \$ 9,452           Cash and cash equivalents         \$ 5,037         62,351           Marketable securities         150         150           Restricted cash         150         150           Accounts receivable         860         263           Inventory         12,266         8,424           Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,594         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         8         72,029         105,455           Intangible assets, net         8         72,029         105,455           Total assets         8         72,029         105,455           Intangible assets, net         8         78,056         10,765           Total assets         8         79,058         10,545           Total assets         8         72,029         105		June 30, 2020 (unaudited)		December 31, 2019	
Cash and cash equivalents         \$ 24,295         \$ 9,452           Marketable securities         5,037         62,351           Restricted cash         150         150           Accounts receivable         860         263           Inventory         12,266         8,424           Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         \$ 72,029         105,455           LABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         S 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         8,91         8,91           Common and preferred stock warrant liability         10,791         8,919<	ASSETS:				
Marketable securities         5,037         62,351           Restricted cash         150         150           Accounts receivable         860         263           Inventory         12,266         8,424           Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         7,202         105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         2         10,76           Current liabilities:         7,036         10,076           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         882         833           Corningent consideration, short-term         882         833           Cornmon and preferred stock warrant liability         10,791         8,919		<b>c</b>	24 205	<b>c</b>	0.450
Restricted cash         150         150           Accounts receivable         860         263           Inventory         12,266         8,424           Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         2,005         2,341           Goodwill         12,026         12,026           Other assets         87         95           Total assets         87         95           Total assets         8,72,029         105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         2         1,545           Current liabilities         7,036         10,076           Accorunts payable         9,084         9,084         3,882           Accorunts payable         9,084         9,084         3,802           Accorunts payable         9,084         9,084         8,092           Accorunts payable         9,084         8,092         8,092 </td <td>·</td> <td>Ф</td> <td>•</td> <td>Ф</td> <td>,</td>	·	Ф	•	Ф	,
Accounts receivable         860         263           Inventory         12,266         8,424           Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use assets, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         87         95           Total assets         \$ 7,028         105,455           LUBILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         2         10,455           Current liabilities         7,036         10,076           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities, long-term         1,594         2,054			•		,
Inventory         12,266         8,424           Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         87         95           Total assets         \$ 72,029         105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         Value of the contract o					
Deferred offering costs         2,506         -           Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         87         95           Total assets         9,084         3,882           Accounts payable         \$ 9,084         3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         5,700         5,700					
Prepaid expenses and other current assets         1,323         1,816           Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         87         95           Total assets         \$ 72,029         105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         ***	•				8,424
Total current assets         46,437         82,456           Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         \$ 72,029         \$ 105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         5,700         5,700			· · · · · · · · · · · · · · · · · · ·		-
Property and equipment, net         7,584         4,427           Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         ***72,029         ***105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT         ****Very Courted state of the country of t					
Right-of-use asset, net         2,005         2,341           Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         72,029         \$ 105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities:           Accounts payable         \$ 9,084         \$ 3,882           Accounts payable         \$ 9,084         \$ 3,882           Account diabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Total current assets		46,437		82,456
Intangible assets, net         3,890         4,110           Goodwill         12,026         12,026           Other assets         87         95           Total assets         \$ 72,029         \$ 105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities:           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Property and equipment, net		7,584		4,427
Goodwill         12,026         12,026           Other assets         87         95           Total assets         \$ 72,029         105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities:           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Right-of-use asset, net		2,005		2,341
Other assets         87         95           Total assets         \$ 72,029         \$ 105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities:           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Intangible assets, net		3,890		4,110
Total assets         \$ 72,029         \$ 105,455           LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities:           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Goodwill		12,026		12,026
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT           Current liabilities:           Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Other assets		87		95
Current liabilities:         Accounts payable       \$ 9,084       \$ 3,882         Accrued liabilities       7,036       10,076         Contingent consideration, short-term       3,500       8,200         Operating lease liabilities, short-term       882       833         Common and preferred stock warrant liability       10,791       8,919         Total current liabilities       31,293       31,910         Operating lease liabilities, long-term       1,594       2,054         Long-term debt       38,558       38,244         Contingent consideration, long-term       4,000       5,700	Total assets	\$	72,029	\$	105,455
Accounts payable         \$ 9,084         \$ 3,882           Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT				
Accrued liabilities         7,036         10,076           Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Current liabilities:				
Contingent consideration, short-term         3,500         8,200           Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Accounts payable	\$	9,084	\$	3,882
Operating lease liabilities, short-term         882         833           Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Accrued liabilities		7,036		10,076
Common and preferred stock warrant liability         10,791         8,919           Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Contingent consideration, short-term		3,500		8,200
Total current liabilities         31,293         31,910           Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Operating lease liabilities, short-term		882		833
Operating lease liabilities, long-term         1,594         2,054           Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Common and preferred stock warrant liability		10,791		8,919
Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Total current liabilities		31,293		31,910
Long-term debt         38,558         38,244           Contingent consideration, long-term         4,000         5,700	Operating lease liabilities, long-term		1,594		2,054
Contingent consideration, long-term 4,000 5,700			,		,
<u> </u>	-				
			75,445		77,908

## Commitments and contingencies

Convertible preferred stock		
Series A convertible preferred stock	3,059	3,059
Series B convertible preferred stock	40,685	40,685
Series C convertible preferred stock	74,575	74,575
Series D convertible preferred stock	142,236	135,039
Stockholders' deficit		
Common stock	1	1
Additional paid-in capital	36,355	33,252
Accumulated deficit	(300,325)	(259,034)
Accumulated other comprehensive loss	(2)	(30)
Total stockholders' deficit	(263,971)	(225,811)
Total liabilities, convertible preferred stock and stockholders' deficit	\$ 72,029	\$ 105,455

# Acutus Medical, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts) (Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,				
		2020	2019		2020		2019
Revenue	\$	1,134	\$ 734	\$	2,717	\$	1,521
Costs and operating expenses:							
Cost of products sold		2,663	2,435		5,857		4,611
Research and development		8,176	5,247		16,149		9,624
Selling, general and administrative		9,125	6,927		19,360		11,020
Change in fair value of contingent consideration		635	 -		(1,584)		
Total costs and operating expenses		20,599	 14,609		39,782		25,255
Loss from operations		(19,465)	(13,875)		(37,065)		(23,734)
Other income (expense):							
Change in fair value of warrant liability and embedded derivative		(2,453)	(1,446)		(1,872)		(605)
Loss on debt extinguishment		-	(1,398)		-		(1,398)
Interest income		95	143		370		208
Interest expense		(1,370)	 (13,769)		(2,724)		(19,511)
Total other expense, net		(3,728)	(16,470)		(4,226)		(21,306)
Net loss	\$	(23,193)	\$ (30,345)	\$	(41,291)	\$	(45,040)
Other comprehensive income (loss)							
Unrealized (loss) gain on marketable securities		(14)	6		(41)		7
Foreign currency translation adjustment		96	2		69		(12)
Comprehensive loss	\$	(23,111)	\$ (30,337)	\$	(41,263)	\$	(45,045)
Net loss per common share, basic and diluted	\$	(32.24)	\$ (45.70)	\$	(58.16)	\$	(68.21)
Weighted-average shares outstanding, basic and diluted		719,421	663,972		709,961		660,333
rroigintod arorago sitatos odistallallig, basic and diluted	_	7 10,421	 000,012		7 00,001		000,000

Cash flows from operating activities         2019           Net loss         \$ (41,291)         \$ (45,040)           Acquisaments to reconcile net loss to net cash used in operating activities:         8 (41,291)         \$ (45,040)           Depreciation expenses         978         1,142           Amontization of intangible assets         2,203         1.32           Stock-based compensation expenses         2,898         1,362           Accretion of discounts/(amortization of premiums) on marketable securities, net         314         17,302           Accretion of discounts/(amortization of premiums) on marketable securities, net         314         17,302           Amontization of district susuace costs         314         17,302           Amontization of district susuace costs         314         17,302           Amontization of district susuace costs         318         1,302           Amontization of district value of warrant liability and embedded derivative         1,872         1,608           Change in fair value of contingent consideration         (5,507)         2,820           Changes in poperating assets and liabilities, net of effect from business combination:         (5,507)         2,820           Inventory         (5,508)         1,502         1,502           Prepaid expenses and other current assets         (5,508		Six Months Ended June 30,				
Net loss         \$ (41,040)         \$ (45,040)           Adjustments to reconcile net loss to net cash used in operating activities:         978         1,142           Depreciation expense         978         1,142           Amonization of intangible assets         220         -           Stock-based compensation expense         2,288         1,362           Accretion of discounts/(amortization of premiums) on marketable securities, net         5         (19)           Amonization of dipti-of-use assets         336         312           Loss on debt extinguishment         1,72         0.05           Change in fair value of contingent consideration         (1,584)         0.05           Change in fair value of contingent consideration         (1,584)         0.05           Change in fair value of contingent consideration         (1,584)         0.05           Change in fair value of contingent consideration         (1,584)         0.05           Change in fair value of contingent consideration         (1,584)         0.05           Change in fair value of contingent consideration         (1,584)         0.05           Change in fair value of contingent consideration         (597)         (280           Inventory         (3,616)         (1,584)         1.05           Inventory			2020			
Adjustments to reconcile net loss to net cash used in operating activities:         978         1,142           Depraciation expense         978         1,42           Amortization of intangible assets         220         -           Stock-based compensation expense         2,898         1,662           Accretion of discounts/(amortization of premiums) on marketable securities, net         5         (19)           Amortization of disbut issuance costs         314         17,309           Amortization of right-of-use assets         314         17,308           Loss on debt extinguishment         1,872         605           Change in fair value of warrant liability and embedded derivative         1,872         605           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Inventory         (3,616)         (1,981)         -           Prepaid expenses and other current assets         666         (43)           Other assets         666         (43)           Other assets         5,266         1,882           Accrued liabilities         1,51         1,810           Operating lease liabilities         4(11)         (349)           Net cash flows from investing activities         2         (22,208)	Cash flows from operating activities					
Depreciation expense         978         1,142           Amortization of intangible assets         220         1.362           Stock-based compensation expense         2,898         1,362           Accretion of discounts/(amortization of premiums) on marketable securities, net         5         (19)           Amortization of debt issuance costs         314         17,309           Amortization of right-of-use assets         336         312           Loss on debt extinguishment         1,872         605           Change in fair value of ordingent consideration         (1,584)         -           Changes in operating assets and isbilities, net of effect from business combination:         (597)         (280)           Inventory         (3,616)         (1,981)         (1,981)           Prepaid expenses and other current assets         666         (43)         (43)           Other assets         8         (12)         (280)           Accounts receivable         5,286         1,882         (280)           Inventory         (3,616)         (1,981)         (1,981)           Other assets         8         (12)         (280)           Accounts payable         5,286         1,882         (220)           Actional payable for sall payable for sall p	Net loss	\$	(41,291)	\$	(45,040)	
Amortization of intangible assets         2,000         .360c/based compensation expense         2,808         1,362           Accretion of discounts/Gamortization of premiums) on marketable securities, net         5         (19)           Amortization of debt issuance costs         314         17,309           Amortization of right-of-use assets         336         312           Loss on debt extinguishment         1,372         605           Change in fair value of varrant liability and embedded derivative         1,572         605           Change in fair value of varrant liabilities, net of effect from business combination:         (1,584)         -           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Accounts receivable         (597)         (280)           Inventory         (3,816)         (1,981)           Prepaid expenses and other current assets         666         (43)           Other assets         666         (43)           Other assets         3         (12)           Accrued liabilities         (410)         (22,081)           Net cash used in operating activities         (411)         (349)           Verash flows from investing activities         17,095         (22,08)           Sales of	Adjustments to reconcile net loss to net cash used in operating activities:					
Stock-based compensation expense         2,898         1,362           Accretion of discounts/(amortization of premiums) on marketable securities, net         5         (19)           Amortization of debt issuance costs         314         17,309           Amortization of right-of-use assets         336         312           Loss on debt extinguishment         -         1,398           Change in fair value of varrant liability and embedded derivative         1,872         605           Change in fair value of contingent consideration         (1,584)         -           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Accounts receivable inventory         (3,616)         (1,961)           Inventory         (3,616)         (1,961)           Prepaid expenses and other current assets         666         (43)           Other assets         8         (12)           Accounts payable         5,286         1,562           Accounts payable         (34,761)         (22,084)           Net cash used in operating activities         (34,761)         (22,084)           Cash flows from investing activities         1,505         -           Purchases of available-for-sale marketable securities         1,000         8,100 <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td>978</td> <td></td> <td>1,142</td>	· · · · · · · · · · · · · · · · · · ·		978		1,142	
Accretion of discounts/amortization of premiums) on marketable securities, net         5         (19)           Amortization of debt issuance costs         314         17,308           Amortization of right-of-use assets         336         312           Loss on debt extinguishment         1,872         605           Change in fair value of warrant liability and embedded derivative         1,872         605           Change in fair value of warrant liabilities, net of effect from business combination:         (597)         (280)           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Accounts receivable         (597)         (280)           Inventory         (3,616)         (1,961)           Prepaid expenses and other current assets         66         (43)           Other assets         8         (12)           Accounts payable         5,266         1,882           Accruded liabilities         155         1,811           Operating lease liabilities         4,411         (3,49)           Nt cash used in operating activities         2         (2,208)           Purchases of available-for-sale marketable securities         1,7095         2           Sales of available-for-sale marketable securities         1,7095 <td>Amortization of intangible assets</td> <td></td> <td>220</td> <td></td> <td>-</td>	Amortization of intangible assets		220		-	
Amortization of debt issuance costs         314         17,309           Amortization of ight-of-use assets         336         312           Loss on debt extinguishment         -         1,398           Change in fair value of warrant liability and embedded derivative         (1,584)         -           Change in fair value of contingent consideration         (1,584)         -           Changes in operating assets and liabilities, net of effect from business combination:         (280)         (280)           Accounts receivable         (597)         (280)         (280)           Inventory         (3,616)         (1,961)	Stock-based compensation expense		2,898		1,362	
Amortization of right-of-use assets         336         312           Loss on debit extinguishment         -         1,398           Change in fair value of warrant liability and embedded derivative         1,872         605           Change in fair value of contingent consideration         (1,584)         -           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Accounts receivable         (597)         (280)           Inventory         (3,616)         (1,981)           Prepaid expenses and other current assets         66         (43)           Other assets         8         (12)           Accounts payable         5,286         1,882           Accrued liabilities         155         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         2         (22,084)           Cash flows from investing activities         5         1,000         8,100           Maturities of available-for-sale marketable securities         1,000         8,100           Sales of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)	Accretion of discounts/(amortization of premiums) on marketable securities, net		5		(19)	
Loss on debit extinguishment         - 1,398           Change in fair value of contingent consideration         (1,584)         - 605           Changes in fair value of contingent consideration         (1,584)         - C           Changes in fair value of contingent consideration         (597)         (280)           Changes in fair value of contingent consideration         (597)         (280)           Inventory         (3,616)         (1,961)           Prepaid expenses and other current assets         666         (43)           Other assets         8         (12)           Accounts payable         5,286         1,682           Accounts payable         5,286         1,682           Accourity payable         (411)         (349)           Net cash used in operating activities         (411)         (349)           Net cash used in operating activities         155         1,810           Purchases of available-for-sale marketable securities         2         (22,208)           Sales of available-for-sale marketable securities         17,095         -           Sale of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash flows from financing activities	Amortization of debt issuance costs		314		17,309	
Change in fair value of ownrant liability and embedded derivative         1,872         605           Change in fair value of contingent consideration         (1,584)         -           Changes in peri value of contingent consideration         (597)         (280)           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Inventory         (3,616)         (1,961)           Prepaid expenses and other current assets         666         (43)           Other assets         8         (12)           Accounts payable         5,286         1,682           Accrued liabilities         (55)         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (411)         (349)           Net cash used in operating activities         5         (22,208)           Cash flows from investing activities           Purchases of available-for-sale marketable securities         7         (22,208)           Adaptive for sale marketable securities         17,095         -           Adaptive for sale marketable securities         17,000         -           Adaptive for sale marketable securities         17,000         - <td>Amortization of right-of-use assets</td> <td></td> <td>336</td> <td></td> <td>312</td>	Amortization of right-of-use assets		336		312	
Change in fair value of contingent consideration         (1,584)         -           Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Accounts receivable         (597)         (280)           Inventory         (3,616)         (1,961)           Prepaid expenses and other current assets         666         (43)           Other assets         86         (42)           Accounts payable         5,286         1,682           Accused liabilities         (411)         (349)           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (34,761)         (22,08)           Purchases of investing activities         -         (22,208)           Sales of available-for-sale marketable securities         17,095         -           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         3,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash flows from financing activities         -         7,000      <	Loss on debt extinguishment		-		1,398	
Changes in operating assets and liabilities, net of effect from business combination:         (597)         (280)           Accounts receivable         (3,616)         (1,961)           Prepaid expenses and other current assets         666         (43)           Other assets         8         (12)           Accounts payable         5,286         1,682           Accrued liabilities         1,555         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         2         (22,088)           Purchases of available-for-sale marketable securities         17,095         -           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash provided by (used in) investing activities         52,650         (17,424)           Cash provided by (used in) investing activities         52,650         (17,000)           Repayment of debt         7,000         1,000         1,000         1,000         1,000         1,000         1,000         1,000         1,000         1,000         1,000         1,000         1,000 <td>Change in fair value of warrant liability and embedded derivative</td> <td></td> <td>1,872</td> <td></td> <td>605</td>	Change in fair value of warrant liability and embedded derivative		1,872		605	
Accounts receivable         (597)         (280)           Inventory         (3.616)         (1.961)           Prepaid expenses and other current assets         666         (43)           Other assets         8         (12)           Accounts payable         5.286         1.682           Accrued liabilities         (411)         (349)           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (411)         (329)           Purchases of available-for-sale marketable securities         -         (22,208)           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Put cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities         -         7,000           Repayment of debt and warrants         -         (2,619)           Repayment of contingual consideration         (2,619)         -           Proceeds from issuance of convert	Change in fair value of contingent consideration		(1,584)		-	
Inventory	Changes in operating assets and liabilities, net of effect from business combination:					
Prepaid expenses and other current assets         666         (43)           Other assets         3         (12)           Accounts payable         5.286         1,682           Accrued liabilities         155         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (34,761)         (22,084)           Cash flows from investing activities           Purchases of available-for-sale marketable securities         17,095         -           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         -         77,000           Repayment of double and warrants         -         77,000           Repayment of susuance of debt and warrants         -         (2,332)           Payment of issuance and extinguishment costs related to debt         -         (2,332)           Payment of issuance and extinguishment costs related to debt         -         (3,315)	Accounts receivable		(597)		(280)	
Other assets         8         (12)           Accounts payable         5,286         1,682           Accrued liabilities         155         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (411)         (349)           Cash flows from investing activities           Purchases of available-for-sale marketable securities         17,095         -           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         52,850         (17,424)           Cash flows from financing activities           Proceeds from issuance of debt and warrants         -         7,000           Repayment of susuance and extinguishment costs related to debt         -         (15,000)           Payment of contingent consideration         (2,619)         -           Proceeds from issuance of convertible preferred stock, net of issuance costs         7         38,226	Inventory		(3,616)		(1,961)	
Accounts payable         5,286         1,682           Accrued liabilities         155         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (34,761)         (22,084)           Cash flows from investing activities         -         (22,088)           Purchases of available-for-sale marketable securities         17,095         -           Sales of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities         -         77,000           Repayment of debt         -         (2,332)           Payment of issuance and extinguishment costs related to debt         -         (2,332)           Payment of issuance and extinguishment costs related to debt         -         38,226           Payment of deferred offering costs         -         38,226           Payment of deferred offering costs         -         38,226           Proceeds from stock options exercises         205         5	Prepaid expenses and other current assets		666		(43)	
Accrued liabilities         155         1,810           Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (34,761)         (22,084)           Cash flows from investing activities           Purchases of available-for-sale marketable securities         -         (22,208)           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         -         (7,000)           Cash flows from financing activities         -         (7,000)           Repayment of debt         -         (2,332)           Payment of issuance and extinguishment costs related to debt         -         (3,300)           Payment of contingent consideration         (2,619)         -           Payment of deferred offering costs         -         38,226           Payment of deferred offering costs         -         38,226           Payment of deferred offering costs         -         38,226	Other assets		8		(12)	
Operating lease liabilities         (411)         (349)           Net cash used in operating activities         (34,761)         (22,084)           Cash flows from investing activities         Secondary of the provided of available-for-sale marketable securities         17,095         2           Purchases of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         2         (3,000)           Net cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities         1         77,000           Repayment of debt         2         77,000           Repayment of issuance and extinguishment costs related to debt         2         (15,000)           Payment of contingent consideration         (26,19)         2           Proceeds from issuance of convertible preferred stock, net of issuance costs         2         38,226           Payment of deferred offering costs         (701)         2           Proceeds from stock options exercises         2         5           Payment of deferred offering costs         (31	Accounts payable		5,286		1,682	
Cash flows from investing activities         (34,761)         (22,084)           Purchases of available-for-sale marketable securities         -         (22,208)           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         52,650         (17,424)           Net cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities         77,000           Proceeds from issuance of debt and warrants         -         77,000           Repayment of debt         -         (15,000)           Payment of issuance and extinguishment costs related to debt         -         (2,332)           Payment of contingent consideration         (2,619)         -           Proceeds from issuance of convertible preferred stock, net of issuance costs         -         38,226           Payment of deferred offering costs         -         37           Proceeds from stock options exercises         205         57           Net cash (used in) provided by financing activities         (3,115)         97,951	Accrued liabilities		155		1,810	
Cash flows from investing activities         Purchases of available-for-sale marketable securities       17,095       -         Sales of available-for-sale marketable securities       40,000       8,100         Maturities of available-for-sale marketable securities       40,000       8,100         Purchases of property and equipment       (4,445)       (316)         Cash paid, net of cash acquired for the Rhythm Xience Acquisition       -       (3,000)         Net cash provided by (used in) investing activities       52,650       (17,424)         Cash flows from financing activities         Proceeds from issuance of debt and warrants       -       77,000         Repayment of debt       -       (15,000)         Payment of issuance and extinguishment costs related to debt       -       (2,332)         Payment of contingent consideration       (2,619)       -         Proceeds from issuance of convertible preferred stock, net of issuance costs       -       38,226         Payment of deferred offering costs       (701)       -         Proceeds from stock options exercises       205       57         Net cash (used in) provided by financing activities       (3,115)       97,951         Effect of exchange rate changes on cash, cash equivalents and restricted cash       14,843 <t< td=""><td>Operating lease liabilities</td><td></td><td>(411)</td><td></td><td>(349)</td></t<>	Operating lease liabilities		(411)		(349)	
Purchases of available-for-sale marketable securities         -         (22,208)           Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities         -         77,000           Repayment of debt         -         (15,000)           Payment of issuance and extinguishment costs related to debt         -         (2,332)           Payment of contingent consideration         (2,619)         -           Proceeds from issuance of convertible preferred stock, net of issuance costs         -         38,226           Payment of deferred offering costs         (701)         -           Proceeds from stock options exercises         205         57           Net cash (used in) provided by financing activities         (3,115)         97,951           Effect of exchange rate changes on cash, cash equivalents and restricted cash         69         (12)           Net change in cash, cash equivalents and restricted cash, at the beg	Net cash used in operating activities		(34,761)		(22,084)	
Sales of available-for-sale marketable securities         17,095         -           Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities           Proceeds from issuance of debt and warrants         -         77,000           Repayment of debt         -         (15,000)           Payment of issuance and extinguishment costs related to debt         -         (2,332)           Payment of contingent consideration         (2,619)         -           Proceeds from issuance of convertible preferred stock, net of issuance costs         -         38,226           Payment of deferred offering costs         -         38,226           Payment of contingent consideration         (2,619)         -           Proceeds from stock options exercises         (701)         -           Porceeds from stock options exercises         (3,115)         97,951           Effect of exchange rate changes on cash, cash equivalents and restricted cash         69         (12)	Cash flows from investing activities					
Maturities of available-for-sale marketable securities         40,000         8,100           Purchases of property and equipment         (4,445)         (316)           Cash paid, net of cash acquired for the Rhythm Xience Acquisition         -         (3,000)           Net cash provided by (used in) investing activities         52,650         (17,424)           Cash flows from financing activities           Proceeds from issuance of debt and warrants         -         77,000           Repayment of debt         -         (15,000)           Payment of issuance and extinguishment costs related to debt         -         (2,332)           Payment of contingent consideration         (2,619)         -           Proceeds from issuance of convertible preferred stock, net of issuance costs         -         38,226           Payment of deferred offering costs         (701)         -           Proceeds from stock options exercises         205         57           Net cash (used in) provided by financing activities         (3,115)         97,951           Effect of exchange rate changes on cash, cash equivalents and restricted cash         69         (12)           Net change in cash, cash equivalents and restricted cash         14,843         58,431           Cash, cash equivalents and restricted cash, at the beginning of the period	Purchases of available-for-sale marketable securities		-		(22,208)	
Purchases of property and equipment (4,445) (316) Cash paid, net of cash acquired for the Rhythm Xience Acquisition - (3,000) Net cash provided by (used in) investing activities 52,650 (17,424)  Cash flows from financing activities  Proceeds from issuance of debt and warrants - 77,000 Repayment of debt - (15,000) Payment of issuance and extinguishment costs related to debt - (2,332) Payment of contingent consideration - (2,619) - (2,332) Payment of deferred offering costs - 38,226 Payment of deferred offering costs - (701) - (700) Proceeds from issuance of convertible preferred stock, net of issuance costs - (701) - (700) Proceeds from stock options exercises - (701) - (700) Proceeds from stock options exercises - (701) - (700) Proceeds from stock options exercises - (701) - (700) Proceeds from stock options exercises - (701) - (700) Proceeds from stock options exercises - (701) - (700) Proceeds from stock options exercises - (701) - (701) Proceeds fro	Sales of available-for-sale marketable securities		17,095		-	
Cash paid, net of cash acquired for the Rhythm Xience Acquisition-(3,000)Net cash provided by (used in) investing activities52,650(17,424)Cash flows from financing activitiesProceeds from issuance of debt and warrants-77,000Repayment of debt-(15,000)Payment of issuance and extinguishment costs related to debt-(2,332)Payment of contingent consideration(2,619)-Proceeds from issuance of convertible preferred stock, net of issuance costs-38,226Payment of deferred offering costs(701)-Proceeds from stock options exercises20557Net cash (used in) provided by financing activities(3,115)97,951Effect of exchange rate changes on cash, cash equivalents and restricted cash69(12)Net change in cash, cash equivalents and restricted cash14,84358,431Cash, cash equivalents and restricted cash, at the beginning of the period9,6029,775	Maturities of available-for-sale marketable securities		40,000		8,100	
Net cash provided by (used in) investing activities       52,650       (17,424)         Cash flows from financing activities       77,000         Proceeds from issuance of debt and warrants       -       77,000         Repayment of debt       -       (15,000)         Payment of issuance and extinguishment costs related to debt       -       (2,332)         Payment of contingent consideration       (2,619)       -         Proceeds from issuance of convertible preferred stock, net of issuance costs       -       38,226         Payment of deferred offering costs       (701)       -         Proceeds from stock options exercises       205       57         Net cash (used in) provided by financing activities       (3,115)       97,951         Effect of exchange rate changes on cash, cash equivalents and restricted cash       69       (12)         Net change in cash, cash equivalents and restricted cash       14,843       58,431         Cash, cash equivalents and restricted cash, at the beginning of the period       9,602       9,775	Purchases of property and equipment		(4,445)		(316)	
Cash flows from financing activitiesProceeds from issuance of debt and warrants-77,000Repayment of debt-(15,000)Payment of issuance and extinguishment costs related to debt-(2,332)Payment of contingent consideration(2,619)-Proceeds from issuance of convertible preferred stock, net of issuance costs-38,226Payment of deferred offering costs(701)-Proceeds from stock options exercises20557Net cash (used in) provided by financing activities(3,115)97,951Effect of exchange rate changes on cash, cash equivalents and restricted cash69(12)Net change in cash, cash equivalents and restricted cash14,84358,431Cash, cash equivalents and restricted cash, at the beginning of the period9,6029,775	Cash paid, net of cash acquired for the Rhythm Xience Acquisition		-		(3,000)	
Proceeds from issuance of debt and warrants  Repayment of debt  Repayment of issuance and extinguishment costs related to debt  Payment of contingent consideration  Proceeds from issuance of convertible preferred stock, net of issuance costs  Payment of deferred offering costs  Payment of deferred offering costs  Proceeds from stock options exercises  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock,	Net cash provided by (used in) investing activities		52,650		(17,424)	
Proceeds from issuance of debt and warrants  Repayment of debt  Repayment of issuance and extinguishment costs related to debt  Payment of contingent consideration  Proceeds from issuance of convertible preferred stock, net of issuance costs  Payment of deferred offering costs  Payment of deferred offering costs  Proceeds from stock options exercises  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock,	Cash flows from financing activities					
Payment of issuance and extinguishment costs related to debt  Payment of contingent consideration  Proceeds from issuance of convertible preferred stock, net of issuance costs  Payment of deferred offering costs  Proceeds from stock options exercises  Proceeds from stock options exercises  Net cash (used in) provided by financing activities  Effect of exchange rate changes on cash, cash equivalents and restricted cash  Net change in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash, at the beginning of the period  (2,332)  (2,619)  (3,619)  (2,619)  (701)  (701)  (701)  (3,115)  (3,115)  (3,115)  (12)  (12)			_		77,000	
Payment of issuance and extinguishment costs related to debt  Payment of contingent consideration  Proceeds from issuance of convertible preferred stock, net of issuance costs  Payment of deferred offering costs  Proceeds from stock options exercises  Proceeds from stock options exercises  Net cash (used in) provided by financing activities  Effect of exchange rate changes on cash, cash equivalents and restricted cash  Net change in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash, at the beginning of the period  (2,332)  (2,619)  (3,619)  (701)  (701)  (701)  (3,115)  (3,115)  (3,115)  (12)  Net change in cash, cash equivalents and restricted cash  (12)  Net change in cash, cash equivalents and restricted cash  (3,431)  (3,431)  (4,843)  (4,843)  (5,8431)  (5,8431)  (6,8431)  (7,843)  (7,843)  (7,843)  (7,843)  (7,843)  (7,843)  (7,843)  (7,844)  (7,843)  (7,843)  (7,844)  (7,84	Repayment of debt		-		(15,000)	
Payment of contingent consideration(2,619)-Proceeds from issuance of convertible preferred stock, net of issuance costs-38,226Payment of deferred offering costs(701)-Proceeds from stock options exercises20557Net cash (used in) provided by financing activities(3,115)97,951Effect of exchange rate changes on cash, cash equivalents and restricted cash69(12)Net change in cash, cash equivalents and restricted cash14,84358,431Cash, cash equivalents and restricted cash, at the beginning of the period9,6029,775	• •		-		, ,	
Proceeds from issuance of convertible preferred stock, net of issuance costs  Payment of deferred offering costs  Proceeds from stock options exercises  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance of convertible preferred stock, net of issuance costs  Proceeds from issuance costs  Pro			(2,619)		-	
Proceeds from stock options exercises 205 57  Net cash (used in) provided by financing activities (3,115) 97,951  Effect of exchange rate changes on cash, cash equivalents and restricted cash  Net change in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash, at the beginning of the period 9,602 9,775			-		38,226	
Proceeds from stock options exercises 205 57  Net cash (used in) provided by financing activities (3,115) 97,951  Effect of exchange rate changes on cash, cash equivalents and restricted cash  Net change in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash, at the beginning of the period 9,602 9,775	Payment of deferred offering costs		(701)		-	
Net cash (used in) provided by financing activities(3,115)97,951Effect of exchange rate changes on cash, cash equivalents and restricted cash69(12)Net change in cash, cash equivalents and restricted cash14,84358,431Cash, cash equivalents and restricted cash, at the beginning of the period9,6029,775					57	
Effect of exchange rate changes on cash, cash equivalents and restricted cash  Net change in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash, at the beginning of the period  9,602  9,775	·					
Net change in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash, at the beginning of the period 9,602 9,775	The cash (assa ii) provided by intalioning assivities		(0,110)		0.,00.	
Cash, cash equivalents and restricted cash, at the beginning of the period 9,602 9,775	Effect of exchange rate changes on cash, cash equivalents and restricted cash		69		(12)	
	Net change in cash, cash equivalents and restricted cash		14,843		58,431	
Cash, cash equivalents and restricted cash, at the end of the period \$ 24,445 \$ 68,206	Cash, cash equivalents and restricted cash, at the beginning of the period		9,602		9,775	
	Cash, cash equivalents and restricted cash, at the end of the period	\$	24,445	\$	68,206	